Search Bar & Filters
Found 66 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of the drug rilvegostomig compared with pembrolizumab as a first-line treatment for patients with metastatic non-small cell lung cancer mNSCLC whose tumors have high levels of PD-L1. This Phase III, randomized, double-blind, global study focuses on patients with mNSCLC who meet specific genetic and health criteria to understand how these treatments perform in this group. Participants receive either rilvegostomig or pembrolizumab, both given intravenously on the first day of each 21-day treatment cycle. The study has two groups one receiving rilvegostomig and the other pembrolizumab, with treatments continuing as part of their first-line cancer care. The trial monitors these treatments over several years to assess long-term outcomes. During the study, participants will have regular assessments including scans to measure tumor response, evaluations of physical function, quality of life questionnaires, and tests to monitor drug levels and immune responses. The main outcomes tracked are overall survival and progression-free survival over approximately five years. Safety and patient-reported symptoms are also closely monitored throughout the study period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of VS-7375, alone and combined with cetuximab or panitumumab, as well as cetuximab plus mFOLFOX chemotherapy, in patients with metastatic colorectal cancer that has a KRAS G12D mutation. This phase 2 study focuses on patients who have either not received prior treatment or have progressed after previous therapies. The goal is to understand how well these treatments work and how safe they are for this specific cancer type. Participants receive one of several treatment regimens VS-7375 alone or combined with cetuximab or panitumumab for patients with second-line or later metastatic colorectal cancer, or VS-7375 combined with cetuximab and mFOLFOX chemotherapy for patients newly diagnosed or with limited prior treatment. The study involves daily oral dosing of VS-7375 and intravenous infusions of the other drugs. Treatments are assigned randomly in a 21 ratio, and participants may cross over between treatments. Throughout the study, participants attend regular visits for evaluations including tumor assessments using RECIST criteria, safety and tolerability monitoring, blood tests for drug levels and tumor markers, and quality of life questionnaires. These assessments occur over periods ranging from 6 months to 2.5 years. The study measures confirmed tumor response rates and monitors for side effects to better understand the potential of these treatments for metastatic colorectal cancer. Participation may last until study completion in late 2028.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of VS-7375, an oral KRAS G12D ONOFF inhibitor, alone and combined with cetuximab in patients with metastatic pancreatic ductal adenocarcinoma PDAC that has the KRAS G12D mutation. This Phase 2, open-label study aims to understand how these treatments work in this specific patient group. The trial is sponsored by Verastem, Inc. and uses a randomized, parallel design.
Actively Recruiting
Researchers are evaluating the safety and effects of L606 in people with pulmonary hypertension caused by interstitial lung disease PH-ILD, WHO Group 3. The study focuses on whether L606 helps participants walk further in six minutes, using the six-minute walk test as a main measure. It also examines how long it takes for PH-ILD to worsen under treatment, alongside close monitoring for any side effects. Participants are randomly assigned to receive either L606, a liposomal form of treprostinil delivered by inhalation with a nebulizer, or a placebo that looks like L606 but contains no active medicine. After the initial blinded phase, participants may join an open-label extension where all receive L606. The study uses a parallel design with quadruple masking to compare outcomes between groups. During the trial, participants will attend visits to assess walking distance at multiple time points, monitor lung health, and watch for side effects. Key measurements include changes in six-minute walk distance at 16 and 24 weeks and the time until worsening events like hospitalization or lung transplant. The study is expected to continue until 2031, with safety and efficacy carefully tracked throughout.
Actively Recruiting
This trial focuses on elderly patients aged 80 years or older, or those 75 years and older who are considered frail, with untreated diffuse large B-cell lymphoma DLBCL and related lymphoma subtypes. The study is a phase III, randomized, open-label, multicenter trial conducted in several countries including Sweden, Norway, Finland, Denmark, Italy, Australia, and New Zealand. It aims to compare the standard chemotherapy regimen R-miniCHOP with an experimental treatment R-pola-miniCHP, where vincristine is replaced by polatuzumab vedotin, to assess differences in outcomes for this patient population. Participants will be randomly assigned to one of two treatment groups. One group will receive R-mini-CHOP consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone over six 21-day cycles. The other group will receive R-pola-mini-CHP, which includes rituximab, cyclophosphamide, doxorubicin, prednisone, and polatuzumab vedotin instead of vincristine, also given over six 21-day cycles. Both treatments last approximately 18 weeks. The study includes a screening period lasting up to 4 weeks before treatment begins. During the study, participants will be followed for up to 36 months after completing treatment to monitor progression-free survival over two years. Researchers will evaluate disease progression and safety outcomes through regular assessments during and after the treatment period. Participants will provide informed consent and undergo evaluations including health status and disease measurements to ensure eligibility and monitor treatment effects throughout the trial.
Actively Recruiting
Researchers are evaluating a potential new medicine called CDR132L to understand its effects on the structure and function of the heart in people living with heart failure. The study focuses on participants with heart failure who have reduced or mildly reduced ejection fraction and left ventricular hypertrophy. This research is a Phase 2, multicenter, randomized, double-blind, placebo-controlled trial aiming to assess safety and efficacy in this population. Participants will receive an intravenous infusion of either CDR132L or a placebo once every four weeks for 48 weeks. Alongside this, all participants will continue their individually tailored guideline-directed standard of care therapy for heart failure. The studys main phase covers these 48 weeks of treatment, followed by monitoring adverse events up to week 60. During the approximately 60-week study, participants undergo evaluations including echocardiography and blood tests measuring biomarkers like microRNA-132-3p and NT-proBNP. Researchers will track changes in heart structure and function, adverse events, and safety throughout the study. The primary outcome focuses on changes in normalized microRNA-132-3p levels from baseline to week 24, while secondary outcomes include measures of heart volume and biomarkers, plus adverse event counts.
Actively Recruiting
Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of divarasib combined with pembrolizumab compared with pembrolizumab plus pemetrexed and carboplatin or cisplatin for adults with KRAS G12C-mutated, advanced or metastatic non-squamous non-small cell lung cancer NSCLC who have not received prior treatment. This phase 3 randomized study aims to find the best first-line therapy option for this specific lung cancer type. Participants are randomly assigned to one of two groups one group receives divarasib orally once daily and pembrolizumab through intravenous infusion every three weeks, while the other group receives pembrolizumab, pemetrexed, and carboplatin or cisplatin all by intravenous infusion every three weeks. The study treatments are given as first-line therapy, and participants are monitored for up to approximately five years. During the study, participants undergo regular assessments including scans to measure tumor response, evaluations of lung cancer symptoms like cough and breathlessness, quality of life questionnaires, and monitoring for side effects. Researchers track progression-free survival and overall survival for up to about five years. Safety and symptom severity are closely followed throughout the study, providing comprehensive data on treatment impact and participant well-being.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of different doses of Pirtobrutinib in adults with chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. Part 1 of the study focuses on participants who have received one to three prior treatments, including a covalent Bruton tyrosine kinase BTK inhibitor, while Part 2 studies treatment-nave participants with a specific genetic deletion 17p deletion. This trial is a Phase 2, open-label, randomized study sponsored by Loxo Oncology, Inc. Participants receive Pirtobrutinib orally in varying doses. In Part 1, three different doses are tested in participants with relapsed or refractory CLLSLL who have prior BTK inhibitor treatment. Part 2 evaluates Pirtobrutinib monotherapy at a standard dose in treatment-nave participants with 17p deletions. The study uses a parallel design with random assignment to treatment groups. Participants are involved for approximately three years in Part 1 and up to two years in Part 2. Researchers monitor overall response rate as the primary outcome, along with duration of response over this time. Participants must be able to swallow oral medication and have their health status regularly assessed, including physical performance scores. Safety and treatment effects are followed throughout the study period.
Actively Recruiting
Researchers are evaluating an investigational eye drop called CA201A, which contains 5% ascorbic acid, to see if it can protect the cornea and reduce the loss of corneal endothelial cells following cataract surgery. This study involves about 200 adults in Australia who are scheduled for cataract surgery and aims to assess the safety and effectiveness of the eye drops in preserving corneal clarity and eye health. Participants will be randomly assigned to receive either the CA201A eye drops or a placebo eye drop without the active ingredient. They will apply one drop to the study eye four times daily starting 7 days before surgery, continuing on the day of surgery, and for 4 weeks after surgery. All participants will undergo standard cataract surgery with usual care, and the study eye drops are given in addition to this routine treatment. During the study, participants will have regular eye examinations including measurements of corneal endothelial cell density and other assessments to monitor the treatments effects and safety. Follow-up will continue for up to 12 weeks after surgery, with total participation lasting about 16 weeks including screening. Researchers will evaluate changes in corneal cells and visual acuity, as well as monitor for any side effects throughout the study.
1-10 of 66
1